Improving the health and quality of life of patients is Boehringer Ingelheim’s goal. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies.
Boehringer Ingelheim concentrate on developing innovative therapies that can extend patients’ lives. In 2017, Boehringer Ingelheim spent around €3.1 billion on research and development, with three sites for human health and a network of more than 20 sites for animal health.
Boehringer Ingelheim are a member of the Psychiatry Consortium. You can find out more about them on their website.
